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S_mary Photodynamic therapy (PDT) has the potential to destroy small tumours with safe healing of
adjacent normal tissue. This study looks at the effects of PDT on the normal pancreas and adjacent tissues in
hamsters using the photosensitiser meso-tetrahydroxyphenylchlorin (mTHPC). Pharmacokinetic studies used
fluorescence microscopy on sections of pancreas, stomach and duodenum 1 h to 6 days after mTHPC. Highest
levels ofsensitiser were seen in the gastric and duodenal mucosa and in the acinar pancreas after 2-4 days. For
PDT, light at 652 nm was delivered by placing a 0.2 mm diameter bare-ended fibre against the tissue. An
energy of 50 J was used 2 or 4 days after 0.1 or 0.3 mg kg-l mTHPC and animals killed I to 7 days later.
Maximum necrosis was seen 3 days after PDT with lesions up to 4 mm in pancreas, 4.5 mm in duodenum and
2.5 mm in stomach. By fractionating the light dose, the lesion size could be increased by 30%. The main
complication was free or sealed duodenal perforation (avoided by shielding the duodenum). Partial, reversible
bile duct obstruction was seen occasionally. There was no macroscopic damage to the bile ducts or major blood
vessels. Apart from the duodenum, all lesions healed safely. In this animal model, only the duodenum was at
risk of serious, irreversible damage. Treatment is likely to be safer in the much thicker human duodenum.
mTHPC is a powerful photosensitiser and suitable for fiurther study for tumours in the region of the pancreas
although care is required near the duodenum.
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Photodynamic therapy (PDT) involves the local activation of
a preadministered photosensitiser by light of a wavelength
matched to the absorption characteristics of the photosensi-
tiser. The activated photosensitiser gives rise to the
production of cytotoxic singlet oxygen (Weishaupt, 1976).
In many publications it has been shown that it is relatively
easy to destroy small volumes of a wide variety of tumours
with PDT (Li et al., 1990: Barr et al., 1991). However, what
matters to a patient is whether the entire tumour volume can
be destroyed without unacceptable damage to adjacent
normal tissues. This means that it is essential to understand
what happens in the region where tumour is invading normal
areas.
Until now little work has been done on this aspect (Bown,
1990). Although much of the interest in PDT has centred
around the possibility ofselective destruction oftumours, this
aspect is almost always over emphasised, and truly selective
destruction of cancers is virtually impossible (Barr et al.,
1990, 1991). Many normal tissues heal mainly by regenera-
tion after PDT, but for tissues like muscle, there is only
partial restoration of function (Chevretton et al., 1992). A
previous report (Schroder et al., 1988) showed that PDT will
produce necrosis in a chemically induced pancreatic cancer in
hamsters using dihaematoporphyrin ether (DHE) but at the
price of duodenal perforation. The most studied photosensi-
tiser, haematoporphyrin derivative (HpD) and purified
fractions thereof (like DHE) are unfortunately far from
ideal. Sulphonated metallophthalocyanines are better (Bown
et al., 1986; Paquette et al., 1988; Peng et al., 1990; Nuutinen
et al., 1991). Their advantages include absorption above
650 nm (giving better light penetration in tissue), photo-
chemical and thermal stability in solution, relatively well-
defined chemistry and less skin photosensitisation (Roberts et
al., 1989; Tralau et al., 1989). Disulphonated aluminium
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phthalocyanine (AlS2Pc) is a more potent photosensitiser
than the tetrasulphonated derivative both in vitro and in vivo
(Chan et al., 1990; Chatlani et al., 1991) and has been studied
in normal pancreas and adjacent tissues in Syrian golden
hamsters (Nuutinen et al., 1991). The results were similar to
those seen with DHE.
Recently, 5-aminolaevulinic acid (5-ALA) has been used as
precursor for the photosensitiser protoporphyrin IX in
studies on PDT in tumours transplanted into the pancreas
of Syrian golden hamsters (Regula et al., 1994). The results
were promising with the fluorescence ratio between tumour
and normal being up to 8:1, PDT necrosis up to 8 mm in
diameter being observed in the tumour, with no evidence of
duodenal perforations. Several other photosensitisers are now
being studied, based on three main types of compounds-
modified porphyrins, chlorins and phthalocyanines.
One of particular interest is meso-tetrahydroxyphenyl
chlorin (mTHPC) which was developed at Queen Mary's
College, London, in 1987 (Berenbaum et al., 1986; Bonnett et
al., 1990; Bonnett, 1993) and is the one used in the present
study. As the testing of various new photosensitisers
proceeded, it was noticed that favourable selectivity was
associated with amphiphilic porphyrins (Bonnett et al., 1989).
The porphyrin macrocycle itself is hydrophobic and so
hydrophilic substituents were needed. Various water-solubilis-
ing groups were tried, particularly SO3H and OH. It was
found that hydroxy phenyl meso-substitution of a porphyrin
gave compounds which showed interesting activity and
selectivity in tumour necrosis. Several compounds of this
type were prepared-the meta (m-THPP), ortho (o-THPP)
and para (p-THPP) isomers. Increased absorption in the red
was achieved by converting the m-THPP by reduction with
diamide into the chlorin m-THPC and into the bacterio-
chlorin m-THPBC. mTHPC is readily prepared in three
stages from pyrrole and m-metroxybenzaldehyde (Bonnett.
1993). It is a pure compound with an absorption peak at
650 nm (Bonnett et al., 1989) which permits better tissue
penetration than at the HpD peak at 630 nm. It has proved
to be a potent photosensitiser, approximately 100 times
stronger than HpD (Savary et al., 1995). This means that the
light doses required are much lower, so treatment times can
be considerably shorter than with other photosensitisers.PDT wi mTHPC aound Om pancres
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In preliminary climcal studies (Ris et al., 1991) this
photosensitiser has been taken up preferentially with up to
14 times more in mesothelioma than in skin and other
normal tissues, although no data were given on the uptake in
normal pleura, the tissue from which mesotheliomas arise. A
light dose of 10 J cm 2 after 0.3 mg kg-' mTHPC caused
10 mm deep tumour necrosis. Patients had to avoid sunlight
for approximately 10 days compared with at least 1 month
after HpD. The tumoricidal effect depended on the mTHPC
dose, the light dose and the time interval between
sensitisation and admninistration. This aspect has been
further studied in BALBc nude mice bearing human
malignant mesothelioma xenografts (Ris et al., 1993). The
depth of necrosis was measured in both the tumour and the
normal skin and muscle of the hind leg. PDT necrosis
occurred in normal tissues treated at times from 4 h to 3 days
after sensitisation and in tumour at times from 12 h to 4
days. The therapeutic ratio between tumour and normal
varied significantly with the time interval between sensitisa-
tion and laser exposure with the greatest selectivity at 3 days.
Despite these reports, there are little data on the effects of
PDT with mTHPC on normal tissues in the gastrointestinal
tract. This study looks at the pharmacokinetics and PDT
effects with mTHPC on the normal pancreas, stomach, bile
duct and duodenum of Syrian golden hamsters to see if there
is potential for treating tumours in these areas, particularly
the pancreas.
Materials and method
mTHPC was supplied by Scotia Pharmaceuticals (Guildford,
UK) as a crystalline solid and dissolved in a solution
composed of 20% ethanol, 30% polyethylene glycol 400
and 50% distilled water. This solution was administered into
the inferior vena cava of female Syrian golden hamsters
(100-120 g) at laparotomy under general anaesthesia from
intramuscular Hypnorm (Fentanyl and fluanisone, Janssen
Pharmaceuticals). The dosage used was 1 mg kg-' for
fluorescence microscopy studies and 0.1 or 0.3 mg kg-' for
photodynamic therapy.
Fluorescence microscopy
Fluorescence microscopy was used to study the distribution
of mTHPC in tissue. Using computerised image processing,
quantification of fluorescence in 10 Mm cryosections was
undertaken for normal pancreas, stomach and duodenum.
Animals were killed and tissues taken for examination at 1
and 4 h and at 1, 2, 3, 4, 5 and 6 days following
administration of 1.0 mg kg-' mTHPC. Two animals were
used for each time point and three sections taken from each
tissue sample. Control sections were taken from unsensitised
animals. This relatively high dose ofmTHPC was required to
generate an adequate fluorescence signal in a reasonable time.
Tissues removed were immediately frozen in a bath of
isopentane (BDH, UK) cooled in liquid nitrogen. Frozen
sections of 10 Mm thickness were cut (Cryostat E microtome,
Reichert) and stored at -70'C. Tissue sections were prepared
and imaged with a minimum of light exposure to avoid
bleaching of the photosensitiser.
An inverted microscope (Olympus IMT-2) with epifluor-
escence and phase-contrast attachments was used (as
previously described by Chan et al., 1989). Fluorescence
excitation was carried out with a 1.8 mW helium-neon laser
operating at 543 nm with the output directed through a
liquid light guide (via a 10 nm bandpass filter to remove
extraneous light) onto a dichroic mirror in the epifluorescence
microscope which incorporated phase-contrast attachments.
Fluorescence was detected in the range 630 to 680 nm via a
combination of bandpass (Omega Optical), a longpass
(Schott RG595) filter and a 10 x objective. The CCD
(charge-coupled device) sensor 578 x 385 pixels (model
P8603, EEV) was cryogenically cooled and imaging opera-
tions and processing were carried out by an IBM AT/PC
clone. The values of mean fluorescence intensities were
calculated by image processing software (Wright Instru-
ments) within rectangular areas of variable size correspond-
ing to sites of interest. No fluorescence photobleaching was
evident under the conditions used. The sections used for
fluorescence microscopy were subsequently stained with
haematoxylin and eosin (H & E) for later visual comparison
using light microscopy and photography. The combination of
phase-contrast microscopy of the frozen sections and light
microscopy of H & E stained adjacent tissue sections enabled
different structures of the tissues (mucosa, submucosa,
muscle, serosa, pancreatic parenchyma and acinar pancreas)
to be identified in the fluorescence image and the fluorescence
intensity of these structures to be measured (Chatlani et al.,
1991).
Photodynamic therapy
The light source used was a pulsed (12 kHz) copper vapour
pumped dye laser (Oxford lasers, Oxford, UK) at a
wavelength of 650 nm, which corresponds to a main
absorption peak of mTHPC. Light was delivered via a
0.2 mm bare-end fibre just touching the surface of the tissue
to be irradiated at laparotomy. As this gives a very high light
irradiance at the fibre tip (160 W cm-2 for 50 mW),
unsensitised control animals were treated first with light at
50 mW and 100 mW to exclude any significant thermal
effects. Light at 100 mW gave considerable thermal effects,
but 50 mW did not, so all the PDT experiments were
undertaken using 50 mW with an exposure time of 1000 s
(50 J). The sites treated were the duodenal lobe of the
pancreas, antral part of the stomach, upper duodenum
(adjacent to the pancreas and bile duct, but clear of the
ampullary region) and the free edge of the lesser omentum.
Only one site was treated in each animal. Two animals were
studied for each combination of variables (drug dose, time
from drug to light and time from PDT to sacrifice). The
experiments were divided into five groups. The total delivered
energy was 50 J (50 mW for 1000 s) in each case, given as a
single fraction except in some animals in group 5.
(1) Light was given 2 or 4 days after sensitisation with
0.3 mg kg-' mTHPC. Only the pancreas was treated and
animals were killed 1, 2, 3, 4 and 7 days after treatment to
detect the time ofmaximum necrosis.
(2) Light was given 2 or 4 days after sensitisation with
0.3 mg kg-' mTHPC. The areas treated were the pan-
creas, stomach, duodenum and free edge of lesser
omentum. Animals were killed 3 days after treatment
(found from section 1 to be the time of maximum
necrosis).
(3) Light was given 2 or 4 days after sensitisation with
0.1 mg kg-' mTHPC. This lower dose of mTHPC was
used to see if it would reduce the incidence of duodenal
perforation and bile duct stenosis. The areas treated were
the pancreas, stomach, duodenum and free edge oflesser
omentum and the animals were killed after 3 days.
(4) Light was given 4 days after sensitisation with
0.1 mg kg -mTHPC. The areas treated were the pan-
creas and the free edge of the lesser omentum but with
'shielding' of the duodenum by gentle mobilisation and
insertion of a piece of opaque paper between the
duodenum and the fibre tip (Nuutinen et al., 1991).
Animals were killed 3 days after PDT.
(5) Light was given either as a single fraction (as in sections
1-4) or in four equal fractions with breaks between
fractions ofeither 1 or 3 min. Light was given 2 or 4 days
after sensitisation with 0.3 mg kg-' mTHPC. Only the
pancreas was treated and animals were killed 3 days after
PDT.In all cases. when the animals were killed, the treated
tissues were studied macroscopically to measure the greatest
and smallest diameter of necrosis and the mean diameter
calculated before microscopic examination.
Results
Fluorescence microscopy
Fluorescence was measured in arbitrary units of counts per
pixel corrected for background levels using sections from
control animals. The relative levels of mTHPC in the
different regions of the pancreas. stomach and duodenum
are shown in Figure 1. In all the tissues studied, the highest
levels of mTHPC fluorescence were seen 4-5 days after
PDT with mTHPC around the pancreas
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sensitisation. In most of the areas studied. there was a lesser
peak at 2 days although the number of animals studied was
not large enough to be sure how significant the dip at 3 days
is. It is most likely due to statistical variations. The estimated
errors in the fluorescence readings are + 15o%. Beyond 4- 5
days. the levels declined rapidly in all tissues except the
pancreatic parenchyma where they fell more slowly. In the
stomach and duodenum. levels were highest in the mucosa
and serosa and lower in the submucosa and muscle (the
duodenal muscle was too thin to make accurate measure-
ments).
Phototherapv studies
In control animals (no mTHPC) treated w-ith 50 J of light
there were no effects on the duodenum or stomach at the
power level of 50 mW. with only verv minor changes in the
pancreas (oedema and necrosis up to 1.0 mm in diameter). In
contrast. if the power was increased to 100 mW. there was
ulceration up to 2.1 mm in the duodenum and 1.5 mm in the
stomach and necrosis up to 2.0 mm in the pancreas. seen in
animals killed 3 days after treatment. Consequentl,. the
power was limited to 50 mW for all subsequent experiments.
Based on the results of the fluorescence studies. for PDT.
light was given on the second or fourth day after sensitisation
in all animals. The results from group 1 looking at the extent
















Figure 2 Mean diameter of the zone of necrosis in normal
pancreas 1-7 days after PDT with 50J of light 2 (0) or 4 (*)












Figure 1 Fluorescence intensity (in arbitrary units of counts per
pixel) as a function of time after administration of
1 mgkg-
I mTHPC in normal hamster pancreas. stomach and
duodenum. Each point is based on three measurements taken
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Figure 3 Mean diameter of zone of necrosis at each treated site 3
davs after PDT with 50J using 0.1 or 0.3 mgkg-'mTHPC (0.I *.
shielded duodenum). The results are combined for treatments
given 2 and 4 days after photosensitisation. so each column is
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shown in Figure 2. The maximum size of PDT lesion was
seen at 3 days, and so in the subsequent experiments animals
were killed 3 days after PDT. Despite the differences in the
fluorescence levels 2 and 4 days after sensitisation, there was
no difference in the size of lesions obtained by treating at
these different times. The same was found for the lesions seen
after treating all the other organs at the two times, so for
further analysis the results for the two times have been
combined. Thus the measurement for the width of the zone
of necrosis was based on four animals for each treatment site
and dose of mTHPC.
The results for the width of necrosis in the pancreas, free
edge of lesser omentum, stomach and duodenum with
mTHPC doses of 0.3 and 0.1 mg kg-1 are shown in Figure 3.
There were two important complications: duodenal
perforation and bile duct obstruction. Duodenal perforation
was the most worrying finding and occurred in at least some
of the animals treated on the pancreas, duodenum or free
edge of lesser omentum. Some perforations were sealed, but
others were not and were associated with peritonitis. The
results are shown in Table I. In the group 1 experiments,
some animals killed 3 or 4 days after PDT showed dilatation
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Figure 4 Fractionation of light. Mean diameter of zone of
necrosis in normal pancreas 3 days after PDT with 50J of light 2
or 4 days after 0.3mgkg 1 mTHPC. The light was given as a
single fraction or as four equal fractions with three breaks of
either 1 or 3min.
Figure 5 Normal pancreas 3 days after PDT using
0.3mgkg'mTHPC given 4 days before the light. Each treated
area received 50J light (50mW for 1000s). The lesion on the left
(arrow) had a single fraction of light, but for that on the right
(arrow), the light was divided into four equal fractions with a
break of 3min between fractions. Scale: 2.0x 1.5mm.
and there was no evidence of free perforation ofthe bile duct.
Dilatation was also seen in some of the animals treated on
the free edge of the lesser omentum, but not for any other
treatment sites, nor when the duodenum was shielded. These
findings are shown in Table II. When the tip of the fibre was
situated in the duodenal lobe of the pancreas it lay
approximately 3 mm from the duodenal wall, 5 mm from
the abdominal aorta and 7 mm from the inferior vena cava,
and in the free edge of the lesser omentum was immediately
adjacent to the bile duct. These findings suggested temporary
biliary obstruction which resolved without serious sequelae
by the seventh day. No perforation of the bile duct or gall
bladder was seen. No biliary obstruction was seen in the
animals treated on the duodenum further away from the
ampulla, so the obstruction was most likely due to oedema at
the ampulla.
No necrosis was seen in the stomach in animals whose
pancreas had been treated, even if the tip of the fibre was
placed in the duodenal lobe of the pancreas only about 3 mm
from the greater curve of the stomach. When the stomach
was treated directly, ulceration was found but there were no
gastric perforations. There was no macroscopic evidence of
damage to the liver parenchyma or major blood vessels
(portal vein, vena cava, abdominal aorta and hepatic artery).
It was because of these complications of PDT with
0.3 mg kg-' mTHPC that the further series of animals were
sensitised with the lower dose of 0.1 mg kg-' and then
treated with the same light dose of 50 J. The dimensions of
the lesions produced with each dose are shown in Figure 3.
With the smaller dose, smaller lesions were seen in the
pancreas and only one animal showed any evidence of bile
duct obstruction (Table II), but sealed duodenal perforations
were still seen in half the animals treated on the pancreas or
free edge of lesser omentum. Perforations could only be
avoided by shielding the duodenum during treatment (Table
I).
The group 5 experiments were designed to assess the
possibility of increasing the PDT effect by fractionating the
light without increasing the total dose delivered. The only site
treated was the pancreas. The results are shown in Figure 4.
In both groups of animals with fractionated therapy (three
breaks of either 1 or 3 min) there was an increase of more
than 30% in the lesion size compared with animals receiving
the same light dose in a single fraction.
Macroscopically, necrosis in the pancreas had a yellowish
white appearance with surrounding oedema. Microscopically,
there were sharply demarcated areas of necrosis (Figure 5).
Acute inflammatory changes were seen in the first couple of
days with lymphocytes and plasma cells by day 3. After 7
days, there was a ring of fibrous tissue around the necrosed
area. Without shielding, necrosis of all layers of the duodenal
wall was seen close to the treated area (Figure 6) and even
10-15 mm away, inflammatory changes were found in the
distal duodenum, proximal jejunum and in the gall bladder.
In the stomach, mucosal ulceration was seen with inflamma-
tory changes in the submucosa, but there were no
perforations.
Table I Duodenal perforation in relation to treatment site in
animals killed 3 days after PDT
Dose Free edge
ofmTHPC oflesser
(mgkg-') Pancreas Stomach Duodenon omentwn
0.3 4 (2) 0 2 3 (3)
0.1 2 (2) - - 2 (2)
0.1 (shielded 0 - - 0
duodenum)
There were four animalsin each group. two treated 2 days and two
treated 4daysafteradministration ofmTHPC (only twoanimals, both
treated at 4 days, in the shielded duodenum group). The figure in the
table is the total number ofperforations, including sealed perforations
(figure in brackets).-, no animals treated at this site with this dose.PDT ulh mTHPC und the pancrea
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Tabie II Bile duct obstruction in relation to treatment site
Timefrom treatment to sacrifice (days)
Site oftreatment 1 2 3 4 7 3
Pancreas 0 0 2 1 0 0
Pancreas - - - - - 0
(shielded duodenum)
Free edge of lesser - - 3 - I
omentum
Free edge of lesser - - - - - 0
omentum (shielded duodenum)
There were four animals in each group, two treated 2 days and two treated 4 days after administration of
mTHPC (only two animals for each site, both treated at 4days, in the shieled duodenum group). All animals
received 0.3mgkg-l mTHPC except those in thefinal column whichonly received0.1 mgkg-'. Thefigure given
is the number ofanimals in which there was macroscopic evidence of a dilated common bile duct. No animals
showed any evidence offree perforations ofthe bile duct.-, no animals treated at this site with this dose.
Fuwejl 6 Duodenum and pancreas 3 days after PDT using
0.1 mgkg'1mTHPC 2 days before 50 J of light Full-thickness
necrosis of the duodenal wall is seen (arrow). Macroscopically,
this animal had a sealed perforation of the duodenum. Scale:
1.3 x 1.0mm.
Dis assi
Photodynamic therapy has attracted most interest because of
the possibility of selective destruction of tumours. Undoubt-
edly there is some selectivity in the uptake of various
photosensitisers in malignant tissue, but unfortunately it is
much more difficult to achieve selective necrosis with any of
the photosensitisers currently available when tumour and
normal tissue are exposed to the same light dose. Thus it is
essential to understand how normal tissues respond to PDT.
As a first step, it is important to know the microscopic
distribution of the photosensitiser, which can be done using
fluorescence microscopy. Considerable differences exist
between different sensitisers. The present work has shown
that mTHIPC levels are highest in the mucosa and serosa of
the stomach and duodenum and in the acinar pancreas and
lower in the submucosa. In contrast, AlS2Pc levels were
highest in the submucosa and bile duct, but low in the acinar
pancreas (Nuutinen et al., 1991). Using aminolaevulinic acid
(ALA), the situation was different again, the levels of the
active derivative, PPIX, being highest in the mucosa but low
in the pancrea (Regula et al., 1994; Loh et al., 1993). Low
levels were seen in muscle with all these photosensitisers.
Comparable data are not available for HpD or DHE.
By far the most vulnerable organ in our experiments was
the duodenum. The highest levels of mTHPC in the
duodenum were in the mucosa, and for ALS2Pc were in the
submucosa, but for both, duodenal perforations were seen in
many animals and could only be avoided by shielding the
duodenum during light exposure (Nuutinen et al., 1991). The
most likely explanation is that both the submucosa and the
muscle layer of the hamster duodenum are extremely thin
(0.06-0.3 mm) which would make them more vulnerable
than the stomach. Earlier work has shown that the main
mechanical strength of the colon after PDT damage comes
from collagen in the submucosa (Barr et al., 1987), and the
same is likely to be true in the duodenum. One would not
expect necrosis in the muscle layer to lead to perforation,
although our results suggest that in the duodenum and the
stomach, the muscle probably plays some part in maintaining
the mechanical integrity of the organ after PDT with
mTlPC, as Nuutinen et al. (1991) suggested for AlS2Pc.
Also, there is no muscularis mucosae in the duodenum so the
submucosa extends into the vili, which have a dense capillary
network supported by collagen tissue (Wheater et al., 1979),
where high fluorescence was detected. In contrast, the
stomach does have a muscularis mucosae, so the submucosa
does not extend into the vili. This could explain the
differences found. The other organ found to be at risk was
the bile duct, although the changes were reversible and there
were no free perforations. These results are similar to those
found with AlS2Pc (Nuutinen et al., 1991). This is reassuring
from the clinical point of view, as it means that PDT is
unliklely to cause a biliary leak. If biliary obstruction
occurred, this could easily be relieved by insertion of a
biliary stent. If the risk was thought to be high, a stent could
be inserted prophylactically.
Thus PDT with mTHiPC in the normal hamster can
produce necrosis in normal pancreas, biliary tree, stomach
and duodenum, but the only organ in which this necrosis
produces serious complications that do not resolve sponta-
neously is the duodenum.
Our main target is to treat tumours of the pancreas. From
results with other photosensitisers, it is likely that using
mTHPC there will be at least as much necrosis in pancreatic
cancers as in the adjacent normal pancreas (Schroder et al.,
1988; Chatlani et al., 1992; Regula et al., 1994), and we have
shown that with the lower dose of sensitiser and shielding of
the duodenum, perforation can be prevented. Also, the
human duodenum is much thicker than that in the hamster,
so may be much more resistant to perforation. Recent clinical
reports using PDT with HpD to treat ampullary tumours
showed a reasonable response with no perforations (Abulafi
et al., 1995; Mlkvy et al., 1995). This suggests that it is likely
to be safe to treat lesions in the human pancreas. Another
potentially important target clinically is tumours of the bile
duct as these may be well localised at the time of diagnosis
and metastasise relatively late. Most of these tumours are
treated initially with stents placed endoscopically. If the stent
were made of a transparent material, PDT could be given
using a light-diffusing fibre placed within the stent and in this
situation any temporary stenosis induced by PDT would not
be a problem as free biliary drainage would already have
been established.
This paper has only looked at PDT effects with mTHPC in
normal tissues in hamsters, but promising experimental
results were reported by Berenbaum et al. (1993) for
transplanted tumours in mice and by Ris et al. (1993) in
1477PDT wf mTHPC mound the pancrm
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transplanted human mesotheliomas in nude mice. Clinical
results are encouraging in preliminary trials on the treatment
of mesothelioma (Ris et al., 1991) and in more extensive
studies on bronchial and oesophageal cancers (Savary et al.,
1995). Our own data showing high levels of fluorescence in
duodenal and gastric serosa confirm the likely value of
mTHPC for sensitising connective tissues and their associated
tumours, although the particularly high levels we saw in the
serosa may be partly due to an artifact as it was difficult to
prevent partial doubling over ofthe serosa during cryosection
preparation.
Much is still to be learnt about the mechanisms of PDT,
particularly the role of oxygen and its availability in the
context of treating tissues in a live animal, but the results
from the last section of our PDT experiments may contribute
a little to this. Our own studies and reports from others
(Messmann et al., 1995; van der Veen et al., 1994) have
shown that the effect of PDT can be enhanced by
fractionating the light dose. The results in the present study
have confirmed this for the first time using mTHPC as the
photosensitiser. The fractionation regimens that we used were
chosen fairly arbitrarily (four equal fractions with breaks
between fractions of either 1 or 3 min), but the diameter of
necrosis produced in the pancreas was increased by about
30% compared with the effect of the same light dose given as
a single fraction (Figure 6). The most likely mechanism is
that the break permits reoxygenation of the tissues being
treated. However, these are only preliminary findings and
further studies are necessary to optimise this effect,
particularly by varying the timing, duration and number of
breaks.
We conclude from these studies that most normal tissues
in the region of the pancreas can tolerate PDT with mTHPC
as the photosensitiser. There is a risk of perforation of the
duodenum in hamsters, but this is likely to be much less in
humans. There is also a risk of biliary stenosis, but this
appears to be reversible. Further studies on an animal model
of pancreatic cancer are now indicated before preliminary
clinical trials.
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